Mou Sudipta Sarker, Gillies Clare, Hu Jiamiao, Danielli Marianna, Al Wattar Bassel Hamameeh, Khunti Kamlesh, Tan Bee Kang
Department of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UK.
Diabetes Research Centre, Leicester General Hospital, Leicester LE5 4PW, UK.
J Clin Med. 2023 Jun 5;12(11):3852. doi: 10.3390/jcm12113852.
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in pregnancy. GDM is associated with serious maternal and fetal complications, in particular, fetal macrosomia and large for gestational age (LGA), which predisposes to a higher risk of childhood obesity and type 2 diabetes mellitus later in life. Early prediction and diagnosis of GDM leads to early interventions such as diet and lifestyle, which could mitigate the maternal and fetal complications associated with GDM. Glycated haemoglobin A1c (HbA1c) has been widely used for monitoring, screening for and diagnosing diabetes and prediabetes. Increasing evidence has also showed that HbA1c could indicate fetal glucose supply. Thus, we hypothesise that the HbA1c level at around 24 to 28 weeks may predict the development of fetal macrosomia or an LGA baby in women with GDM, which could be useful for better prevention of fetal macrosomia and LGA. We searched MEDLINE, EMBASE, Cochrane and Google Scholar databases from inception to November 2022 for relevant studies that reported at least one HbA1c level during 24-28 weeks of pregnancy and fetal macrosomia or an LGA baby. We excluded studies that were not published in the English language. No other search filters were applied during the search. Two independent reviewers selected eligible studies for meta-analysis. Two independent reviewers performed data collection and analyses. The PROSPERO registration number is CRD42018086175. A total of 23 studies were included in this systematic review. Of these, 8 papers reported data of 17,711 women with GDM that allowed for inclusion in a meta-analysis. The obtained results demonstrated the prevalence of fetal macrosomia was 7.4% and of LGA, 13.36%. Meta-analyses showed that the estimated pooled risk ratio (RR) for LGA in women with high HbA1c values compared to normal or low values was 1.70 (95% CI: 1.23-2.35), = 0.001; and the pooled RR for fetal macrosomia was 1.45 (95% CI: 0.80 to 2.63), = 0.215. Further research is needed to evaluate the utility of HbA1c levels in predicting the delivery of a baby with fetal macrosomia or LGA in pregnant women.
妊娠期糖尿病(GDM)是妊娠期间最常见的代谢紊乱疾病。GDM与严重的母婴并发症相关,尤其是巨大儿和大于胎龄儿(LGA),这会使儿童期肥胖和日后患2型糖尿病的风险更高。GDM的早期预测和诊断能够带来饮食和生活方式等早期干预措施,从而减轻与GDM相关的母婴并发症。糖化血红蛋白A1c(HbA1c)已被广泛用于监测、筛查和诊断糖尿病及糖尿病前期。越来越多的证据还表明,HbA1c能够反映胎儿的葡萄糖供应情况。因此,我们推测,妊娠24至28周左右的HbA1c水平可能预测GDM女性胎儿巨大儿或LGA婴儿的发生,这对于更好地预防胎儿巨大儿和LGA可能有用。我们检索了MEDLINE、EMBASE、Cochrane和谷歌学术数据库,从建库至2022年11月,查找报告了妊娠24 - 28周期间至少一个HbA1c水平以及胎儿巨大儿或LGA婴儿情况的相关研究。我们排除了非英文发表的研究。检索过程中未应用其他检索筛选条件。两名独立评审员选择符合条件的研究进行荟萃分析。两名独立评审员进行数据收集和分析。PROSPERO注册号为CRD42018086175。本系统评价共纳入23项研究。其中,8篇论文报告了17711名GDM女性的数据,这些数据可纳入荟萃分析。所得结果显示,胎儿巨大儿的患病率为7.4%,LGA的患病率为13.36%。荟萃分析表明,与正常或低值相比,高HbA1c值女性发生LGA的估计合并风险比(RR)为1.70(95%CI:1.23 - 2.35),P = 0.001;胎儿巨大儿的合并RR为1.45(95%CI:0.80至2.63),P = 0.215。需要进一步研究来评估HbA1c水平在预测孕妇分娩胎儿巨大儿或LGA婴儿方面的效用。